Agilent
Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics, and
applied chemical markets, and BaseSolve, a leading provider of advanced
bioinformatic analysis and reporting, today announced a U.S.-focused
co-marketing agreement to offer customers a powerful, integrated solution for
Next-Generation Sequencing (NGS) workflows. This co-marketing agreement applies
exclusively to customers within the United States region.
The
collaboration will provide laboratories in the U.S. with a streamlined NGS
workflow solution beginning with quality control of the sample, followed by
library preparation and Target Enrichment and ending with data reporting. The
integrated offering combines Agilent’s portfolio of trusted genomics
instrumentation and reagents with BaseSolve’s innovative software solutions.
This workflow has been optimized for both Element and Illumina sequencers in
the U.S.
Integrated
Technologies for Precision Genomics
The
agreement focuses on delivering a tested and supported integrated solution.
Agilent’s
Genomics Systems:
Agilent
provides a comprehensive suite of tools for sample and library preparation, and
quality control, including SureSelect, Avida, Magnis, NGS Bravo/NGS Bravo
Workstation, TapeStation, Fragment Analyzer, and Femto Pulse Automated
Electrophoresis Systems.
BaseSolve’s
Bioinformatic Platform:
BaseSolve
offers sophisticated bioinformatic analysis and reporting through its
flagship AUGMETTM platform. AUGMETTM is an end-to-end
analysis and reporting suite designed to support NGS workflows, focusing on
accuracy, scalability, and compliance.
This
collaboration is particularly aimed at enhancing the Whole Exome Sequencing
(WES) and Whole Transcriptome Sequencing (WTS) workflows, providing a pathway
for research laboratories to adopt the combined solution efficiently.
"This
co-marketing agreement with BaseSolve is a testament to our commitment to
accelerating genomics and scientific discovery," said Majken Nielsen, Vice
President Clinical Businesses, Clinical Diagnostics Division at Agilent
Technologies. "By pairing our robust, high-quality sample prep and
automation systems with BaseSolve’s expert bioinformatic analysis, we are
removing complexity and enabling our research customers to achieve rapid,
reliable, and standardized results in their labs."
"The
fully executed co-marketing agreement with Agilent marks an exciting milestone
for BaseSolve and our AUGMETTM platform," said Dr. Anupam J
Das. "Customers can now easily access an integrated solution that
leverages the quality of Agilent's instrumentation with our advanced analysis
and reporting capabilities. We look forward to supporting translational
research labs globally, particularly within the United States where this
solution is immediately accessible through Agilent's quoting structure."
About
Agilent Technologies
Agilent
Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics,
and applied chemical markets, delivering innovative solutions that help
customers gain the insights they seek. Agilent's instruments, software,
services, solutions, and consumables are used by laboratories worldwide to
address the full scope of their scientific needs.
About
BaseSolveTM
BaseSolve
Informatics Private Limited is a global provider of cutting-edge bioinformatic
analysis and reporting solutions for research laboratories. Its flagship
platform, AUGMETTM, delivers end-to-end support for complex genomics
workflows. BaseSolve is committed to scalable, compliant, and accurate data
analysis.
Contact
Dr.
Anupam J Das, PhD
Cofounder
& COO BaseSolve Informatics
https://www.basesolve.com
| https://augmet.ai
Melanie
Herscovitch, PhD
Market
Specialist Manager, AFO
Healthcare
Diagnostics